Search
Research
National Hybrid Closed-Loop Outpatient TrialThe national Hybrid Closed-Loop Outpatient Trial will test the use of an automated insulin delivery system to see if it is better at optimising blood glucose levels than standard therapy.
Research
Dietary patterns during pregnancy and maternal and birth outcomes in women with type 1 diabetes: the Environmental Determinants of Islet Autoimmunity (ENDIA) studyDietary patterns characterised by high intakes of vegetables may lower the risk of pre-eclampsia and premature birth in the general population. The effect of dietary patterns in women with type 1 diabetes, who have an increased risk of complications in pregnancy, is not known.
Research
Benefits, implementation and sustainability of innovative paediatric models of care for children with type 1 diabetes: a systematic reviewThe evidence about the acceptability and effectiveness of innovative paediatric models of care for Type 1 diabetes is limited. To address this gap, we synthesised literature on implemented models of care, model components, outcomes, and determinants of implementation and sustainability.
Research
Outcomes and experiences of families with children with type 1 diabetes on insulin pumps through subsidised pump access programs in Western AustraliaIn Australia, access to insulin pump therapy for children with type 1 diabetes is predominantly restricted to families with private health insurance. In an attempt to improve equity, additional subsidised pathways exist which provide pumps to families with reduced financial resources. We aimed to describe the outcomes and experiences of families with children commenced on pumps through these subsidised pathways in Western Australia.
Research
The Benefits to Bone Health in Children and Pre-School Children with Additional Exercise Interventions: A Systematic Review and Meta-AnalysisDetermine if exercise interventions, beyond what is already provided to children and preschool children, improve bone health and reduce fracture incidence.
Research
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative reviewThe National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenne (CE) marking without an initial national assessment. The regulatory process for CGM CE marking, in contrast to the Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) process, is described.
Research
Improving epinephrine responses in hypoglycemia unawareness with real-time continuous glucoseThe objective of this study was to determine whether real-time continuous glucose monitoring (CGM) with preset alarms at specific glucose levels would prove...
Research
Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapyThe advent of sensor-augmented pump therapy with a low-glucose suspend (LGS) function.
Research
High incidence of obesity co-morbidities in young children: A cross-sectional studyThe prevalence of overweight and obesity in children is a public health problem because of future morbidity.
Research
Acute hyperglycaemia does not alter nitric oxide-mediated microvascular function in the skin of adolescents with type 1 diabetesImpact of an acute bout of hyperglycaemia on nitric oxide (NO)-mediated microvascular function in the skin of adolescents with type 1 diabetes